Update shared on 26 Nov 2025
Fair value Decreased 11%Analysts have lowered their price target for Camlin Fine Sciences from ₹270 to ₹240. They cite updated estimates that reflect improved profit margins and revenue growth, along with a reduced valuation multiple.
What's in the News
- At the Board Meeting held on November 10, 2025, the re-appointment of Mr. Mahabaleshwar Palekar as Non-Executive Independent Director was approved, and unaudited financial results for the quarter and half year ended September 30, 2025, were reviewed (Board Meeting).
- A Special/Extraordinary Shareholders Meeting is scheduled for December 13, 2025, through postal ballot in India (Shareholders Meeting).
- On October 29, 2025, a Special/Extraordinary Shareholders Meeting was held to consider the issuance of equity shares on a preferential basis via a share swap arrangement (Shareholders Meeting).
- The Board Meeting on September 29, 2025, approved a proposal for preferential allotment of equity shares for the acquisition of a majority equity stake in Vinpai via a share swap arrangement, subject to regulatory and shareholder approval (Board Meeting).
Valuation Changes
- The consensus analyst price target has decreased from ₹270 to ₹240, reflecting a lower fair value assigned to the shares.
- The discount rate has risen slightly from 13.94% to 14.00%.
- The revenue growth estimate has increased marginally from 20.54% to 20.84%.
- The net profit margin expectation has improved from 6.96% to 8.91%.
- The future P/E ratio projection has fallen significantly from 42.4x to 29.4x, indicating a reduced valuation multiple.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.